Price to book forward of Sotera Health Company – NASDAQ:SHC
This article provides access to the "Price to book forward" financial metric for Sotera Health Company (SHC) on the Nasdaq stock market via TradingView. It indicates that the market was closed at the time of viewing and that there were no recent trades. The content primarily serves as a gateway to financial data and various tools offered by the TradingView platform.
Price to earnings forward of Sotera Health Company – NASDAQ:SHC
The article presents financial data for Sotera Health Company (NASDAQ: SHC), specifically focusing on its Price to Earnings (P/E) forward ratio. The content is primarily a data display page from TradingView, offering an overview of the company's financials without detailed analysis. It indicates that the market was closed at the time of viewing with no trades recorded.
1 Profitable Stock Worth Your Attention and 2 We Brush Off
This article identifies one profitable stock to buy and two to potentially avoid, based on StockStory's analysis of financial strength and long-term sustainability. TransDigm (TDG) is recommended due to strong organic growth and free cash flow, while Sotera Health (SHC) and Atmus Filtration Technologies (ATMU) are flagged for concerns regarding organic revenue growth, margins, and capital consumption.
Sotera Health (SHC) Could Be 12% Undervalued As Russell Index Removal Stirs Volatility
Sotera Health (SHC) has been removed from several Russell growth indexes, causing potential short-term volatility, yet the stock is considered 12% undervalued based on a modeled fair value of $20.22 against its current trading price of $17.75. The company's proactive compliance with evolving EPA regulations for ethylene oxide (EtO) sterilization positions it for growth despite risks such as stricter rules and high compliance costs. Investors are encouraged to assess the balance of risks and rewards and explore other investment opportunities through the Simply Wall St Screener.
Price to sales forward of Sotera Health Company – NASDAQ:SHC
This article provides a brief financial overview of Sotera Health Company (NASDAQ: SHC), specifically focusing on its price-to-sales forward metric. It indicates that the company's financial data on this metric is available for different periods and values, emphasizing its availability through the TradingView platform.
Does Sotera Health's (SHC) Russell Index Exit Quietly Reshape Its Long-Term Investor Base Narrative?
Sotera Health (SHC) was removed from several Russell growth indices on June 27, 2026, which could alter its shareholder base and trading profile. This index exclusion affects who owns the stock rather than its operational fundamentals, with near-term catalysts and long-term risks around ethylene oxide regulation and litigation remaining key. The company recently completed a share offering and term loan repricing to support its balance sheet flexibility and growth objectives.
Sotera Health Company(NasdaqGS: SHC) dropped from Russell 2500 Growth Benchmark
Sotera Health Company (NasdaqGS:SHC) has been removed from the Russell 2500 Growth Benchmark. The article provides a company profile outlining its services in sterilization and lab testing, along with recent news including lock-up agreements, conference presentations, and Q1 2026 earnings with a revenue forecast of $1.23B to $1.25B and adjusted EPS of $0.93 to $1.01. Analysts currently have a "BUY" consensus for SHC, with an average target price of $20.22.
Enterprise value to revenue forward of Sotera Health Company – NASDAQ:SHC
This article provides financial data for Sotera Health Company (NASDAQ: SHC), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial analysis platform like TradingView, detailing various financial metrics and market information for the company.
Sotera Health shares, sector peers and risk management in focus
Sotera Health (SHC) shares, listed on NASDAQ, specialize in health services for medical device and pharmaceutical manufacturers, focusing on sterilization and lab testing. The company's business model, which includes Sterigenics, Nordion, and Nelson Labs, provides risk-management services that are recurring and create long-term customer relationships. Regulatory scrutiny on sterilization methods, particularly EO, impacts the industry, influencing Sotera Health's operational costs and emphasizing expertise in a consolidated market.
Sotera Health Company Actuals & Estimates (NASDAQ:SHC)
This article provides an overview of Sotera Health Company (NASDAQ: SHC) stock, including its current price, historical performance, and analyst forecasts. It also details financial metrics such as market capitalization, earnings per share, revenue, and EBITDA, along with information on future earnings reports and investment guidance.
Sotera Shareholder Action Reminder
Faruqi & Faruqi, LLP reminds investors of the March 27, 2023 deadline to seek the role of lead plaintiff in a federal securities class action filed against Sotera Health Company (NASDAQ: SHC). The lawsuit alleges that Sotera made false and misleading representations regarding its emissions control systems and exposure to liability from lawsuits concerning its EtO emissions, which led to artificially inflated stock prices. The company's stock price significantly declined after a jury found Sotera liable for a plaintiff's cancer due to "willful and wanton" misconduct related to toxic EtO emissions.
3 Promising Stocks Trading 25.2% to 33.7% Below Intrinsic Value Estimates
Amidst a fluctuating U.S. market, three stocks—Sotera Health (SHC), American Healthcare REIT (AHR), and Toast (TOST)—are identified as trading significantly below their intrinsic value estimates. These companies show promising long-term growth potential and strong earnings forecasts, making them attractive opportunities for value-seeking investors despite some individual financial challenges like debt or dilution.
Sotera Health Is Maintained at Overweight by Barclays
Barclays has reiterated its 'Overweight' rating on Sotera Health (SHC) stock. This indicates the firm's positive outlook on the company's performance. The detailed analyst report likely provides further insights into this decision.
Barclays Maintains Sotera Health Company(SHC.US) With Buy Rating, Raises Target Price to $19
Barclays has reiterated its Buy rating on Sotera Health Company (SHC.US) and increased its price target from $17 to $19. This adjustment reflects the analyst's updated valuation for the company.
Should Surging Institutional Ownership and Profitability Gains Require Action From Sotera Health (SHC) Investors?
Sotera Health recently reported improved quarterly revenue and a significant year-over-year jump in net profit, ranking 23rd among healthcare peers. Concurrently, institutional investors now hold almost 94.60% of Sotera’s shares, reflecting a sharp increase and major position changes by top holders. This article analyzes how the surging institutional ownership and profitability gains might influence Sotera Health’s investment outlook, highlighting financial improvements alongside ongoing risks from ethylene oxide litigation.
Sotera Health Co (SHC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
Sotera Health Co (SHC) revenue breakdown data indicates that as of the most recent disclosure, the United States accounted for 54.10% of its revenue, totaling $629.54 million. Following the U.S., Europe contributed 19.95% ($232.18 million) and Canada contributed 19.07% ($221.95 million) of the company's revenue. The company has not yet disclosed relevant data for its business segments or for fiscal years 2019-2025.
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
This article evaluates three healthcare stocks, recommending one for long-term investment while advising against two others. Natera (NTRA) is highlighted as a strong buy due to elevated product demand, rising operating profits, and positive free cash flow. In contrast, Sotera Health Company (SHC) and Avantor (AVTR) are deemed less favorable due to stagnant organic growth, declining profitability, and modest revenue bases.
Sotera Health Co Stock (US8293551086): Earnings Metrics In Focus After Recent Quarterly Update
This article focuses on how investors are evaluating Sotera Health Co (SHC) after its latest quarterly earnings report. Key metrics such as revenue trends, margin dynamics, cash flow, and balance sheet signals are being scrutinized to assess the company's performance, financial health, and future prospects. The report serves as a critical benchmark for both short-term sentiment and long-term investment decisions for the healthcare services provider.
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
This article identifies one healthcare stock, Natera (NTRA), as a long-term investment opportunity due to its strong product demand, increased operating profits, and positive free cash flow. Conversely, it advises against investing in Sotera Health Company (SHC) and Avantor (AVTR), citing concerns about modest organic sales, capital intensity, and underperforming core businesses. The author provides brief rationales for each recommendation, encouraging readers to access in-depth research reports.
Certain Stock Options of Sotera Health Company are subject to a Lock-Up Agreement Ending on 11-JUN-2026.
Certain stock options of Sotera Health Company (SHC) are under a 31-day lock-up agreement, preventing executive officers, directors, and selling stockholders from trading them. This lock-up period began on May 11, 2026, and concludes on June 11, 2026. The agreement is in place to stabilize the market after a recent offering.
Sotera Health (SHC) Valuation After Goldman Coverage Legal Clarity And Earnings Beat
Sotera Health (SHC) is gaining momentum following Goldman Sachs' initiation of coverage, a strong Q1 2026 earnings beat, and clarity on Ethylene Oxide legal issues. The stock is currently trading at US$16.53, with analysts suggesting an intrinsic discount and upside to targets. While fair value estimates point to the stock being 18% undervalued with a target of US$20.13, its P/E ratio of 40x against a fair ratio of 26.5x suggests it might be expensive on that metric.
Sotera Health (SHC) Valuation After Goldman Coverage Legal Clarity And Earnings Beat
Sotera Health (SHC) recently received coverage from Goldman Sachs, reported better-than-expected Q1 2026 earnings, and clarified legal exposures related to Ethylene Oxide. The company trades at an 18% undervaluation based on a fair value estimate of US$20.13, driven by strong cash generation and predictable revenue. However, its current P/E ratio of 40x appears expensive compared to a fair ratio of 26.5x and the industry average, suggesting less room for error.
Sotera Health Company (SHC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Sotera Health Company (SHC) recently participated in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, where they outlined a planned CEO transition for 2026 and a strategic planning initiative for long-term growth. The company reported robust Q1 performance with 6.5% constant currency revenue growth and 20 basis points EBITDA margin expansion, while also detailing investments in compliance with new NESHAP regulations. Upcoming legal challenges related to ethylene oxide emissions and a reevaluation of the 2016 IRIS value were also discussed as potential impacts on future litigation.
Geode Capital Management LLC Acquires 476,365 Shares of Sotera Health Company $SHC
Geode Capital Management LLC has increased its stake in Sotera Health Company (NASDAQ:SHC) by 13.8%, purchasing an additional 476,365 shares. This acquisition brings their total holdings to 3.93 million shares valued at approximately $69.4 million. Sotera Health recently reported strong Q1 results, surpassing earnings and revenue expectations, and the stock maintains a "Moderate Buy" rating from analysts, despite a significant insider share sale by GTCR Investment XI LLC.
Sotera Health Co stock (US8293551086): investors eye litigation overhang and growth in sterilization
Sotera Health Co faces investor scrutiny due to ongoing litigation risks alongside steady demand for its sterilization and lab testing services. The company is a key provider of sterilization for medical devices and pharmaceuticals, benefiting from regulatory requirements for product safety and contamination control. While essential to healthcare supply chains, its use of technologies like ethylene oxide subjects it to environmental scrutiny and potential legal challenges, which remain a significant factor in its valuation.
Did Goldman Sachs’ Legal-Risk Reassessment Just Shift Sotera Health's (SHC) Investment Narrative?
Goldman Sachs recently initiated coverage on Sotera Health (SHC) with a "Buy" rating and a US$20.00 price target, highlighting the company's strong business model and progress in resolving personal injury lawsuits. This reassessment of legal risk by Goldman Sachs could significantly alter Sotera Health's investment narrative and risk-reward balance, despite ongoing concerns about unresolved ethylene oxide (EO) litigation in some states. The company's recent US$486 million equity offering also provides financial flexibility for emissions compliance and capacity investments, supporting its growth in sterilization volumes.
Goldman Sachs initiates Sotera Health stock with buy rating on durable model
Goldman Sachs initiated coverage on Sotera Health Co. (NASDAQ: SHC) with a Buy rating and a price target of $20.00, citing its durable model, attractive valuation, and market leadership in sterilization and lab testing services. The investment bank highlighted the company's consistent revenue growth, high-margin profile, and insulation from supply chain volatility due to its vertical integration, including being a leading supplier of Cobalt-60. Recent legal clarifications regarding personal injury lawsuits also provide increased financial clarity for the company.
Goldman Sachs initiates Sotera Health stock with buy rating on durable model
Goldman Sachs has initiated coverage on Sotera Health Co. (SHC) with a Buy rating and a $20 price target, citing its durable business model, vertical integration, and attractive valuation. The firm highlighted Sotera's strong position as a provider of sterilization and lab testing services to medical device and pharmaceutical companies, consistent revenue growth, and high gross profit margin. Recent legal clarity and strong Q1 2026 results further support the positive outlook.
Sotera Health Co stock (US8293551086): Nasdaq-listed sterilization group in focus after recent earni
Sotera Health Co (SHC) shares are under investor scrutiny on Nasdaq following its latest quarterly results and ongoing litigation and regulatory challenges in the US. The company, a major sterilization and lab-testing provider, faces balancing growth with cost inflation and legal proceedings related to historical emissions. Investors are closely monitoring company reports and operational execution due to the absence of recent verified analyst coverage.
Sotera Health launches 31.8M share secondary offering
Sotera Health has announced a secondary offering of 31.8 million shares of its common stock. The selling stockholders will receive all proceeds from this offering. The decision follows a previous announcement regarding a 25 million share offering by the company.
Sotera Health (SHC) director awarded 14,970 RSUs, now holds 89,882 shares
Sotera Health director David E. Wheadon received an equity grant of 14,970 restricted stock units (RSUs) as part of his compensation. This grant, made under the company's 2020 Omnibus Incentive Plan, vests in full on the earlier of one year or prior to the next annual shareholders meeting, provided he remains a director. Following this award, Mr. Wheadon's total holdings in Sotera Health amount to 89,882 shares and RSUs.
Sotera Health (SHC) director awarded 14,970 RSUs as equity compensation
Sotera Health (SHC) director Kyle Richard G was granted 14,970 Restricted Stock Units (RSUs) as equity compensation on May 22, 2026. These RSUs, which represent the right to receive one share of common stock each, will vest in full on the earlier of the first anniversary of the grant date or immediately before the company's next annual shareholders meeting, contingent on his continued service as a non-employee director. This transaction is considered a routine equity compensation event aimed at aligning director interests with those of shareholders.
Sotera Health (SHC) CEO awarded large RSU and performance SAU grants
Sotera Health's CEO, Alton Shader, received substantial equity awards on May 26, 2026, including 203,634 RSUs, an additional 375,939 RSUs, and 101,817 performance-based Share Appreciation Units (SAUs). These grants, issued at no cash cost, are part of the company's 2020 Incentive Plan and generally vest in three equal annual installments starting March 2, 2027, with SAUs also contingent on stock-price-related performance. Following these awards, Shader directly holds 579,573 common shares and 101,817 SAUs.
Sotera Health (SHC) director awarded 14,970 RSUs as equity compensation
Sotera Health director Kenneth D. Krause was granted 14,970 restricted stock units (RSUs) as equity compensation on May 22, 2026. These RSUs, which represent the right to receive one common share each, will vest fully on the earlier of the first anniversary of the grant date or immediately before the next annual shareholders meeting, contingent on his continued service as a non-employee director. This non-cash award, reported via a Form 4 SEC filing, falls under the company's 2020 Omnibus Incentive Plan and reflects an increase in Krause's direct holdings to 14,970 shares post-transaction.
Sotera Health (SHC) director Ann R. Klee granted 14,970 RSUs as equity award
Sotera Health (SHC) director Ann R. Klee was granted 14,970 Restricted Stock Units (RSUs) on May 22, 2026, as an equity award under the company's 2020 Omnibus Incentive Plan. These RSUs, which represent the right to receive one share of common stock each, will vest fully on the earlier of the first anniversary of the grant date or immediately before the next annual shareholders' meeting, provided she continues her service as a non-employee director. Following this grant, Klee's total holdings in Sotera Health consist of 14,970 RSUs and 125,956 shares of common stock, totaling 140,926 units and shares.
Sotera Health (NYSE: SHC) CEO Alton Shader files initial insider Form 3
Sotera Health Co (NYSE: SHC) CEO Alton Shader has filed an initial Form 3, establishing his status as an insider. The filing indicates no reported share transactions or derivative positions, nor any existing holdings. This Form 3 merely serves as an initial notification of beneficial ownership, without disclosing any buying or selling activity.
Sotera Health (SHC) awards 14,970 RSUs to director Vincent Petrella
Sotera Health (SHC) director Vincent K. Petrella was granted 14,970 restricted stock units (RSUs) on May 22, 2026, as director compensation under the company's 2020 Omnibus Incentive Plan. These RSUs vest on the earlier of the first anniversary of the grant date or immediately before the next annual shareholders' meeting, contingent on his continued service. Following this grant, Petrella's total holdings in Sotera Health consist of 95,751 shares and RSUs.
Sotera Health (SHC) director Sean Cunningham receives 14,970 RSU equity grant
Sotera Health director Sean Laurence Cunningham received an equity grant of 14,970 restricted stock units (RSUs) as part of his board compensation on May 22, 2026. These RSUs, which represent the right to receive one share of common stock each, will vest fully on the earlier of one year from the grant date or immediately before the next annual shareholders meeting, contingent on his continued service as a non-employee director. Following this grant, Cunningham's total holdings in Sotera Health amount to 95,751 units and shares, comprising the newly granted RSUs and 80,781 shares of common stock.
3 Stocks Estimated To Be Trading Up To 44.8% Below Intrinsic Value
This article identifies three U.S. stocks—Sotera Health (SHC), Allison Transmission Holdings (ALSN), and Glacier Bancorp (GBCI)—that appear to be trading significantly below their estimated intrinsic value based on future cash flows. Each company operates in a different sector, showing strong projected earnings growth but also highlighting specific financial concerns like interest payment coverage or debt coverage. The report emphasizes the potential for long-term investors in these undervalued companies within a robust U.S. market.
A Look At Sotera Health (SHC) Valuation After Strong Q1 Beat And Upgraded Full Year Outlook
Sotera Health (SHC) reported strong Q1 revenue of US$280 million, exceeding analyst expectations and leading to an upgraded full-year outlook. Despite this positive performance and reduced interest costs, the stock is down year-to-date, prompting a valuation check. Analysts currently assess SHC as undervalued with a fair value of $20.13, although the valuation is sensitive to various assumptions about growth, profitability, and potential risks like ethylene oxide litigation.
Sotera Health shareholders elect directors and approve executive pay at annual meeting
Sotera Health shareholders recently held their 2026 annual meeting, electing four Class III directors and approving executive compensation. The company, trading near its InvestingPro Fair Value, also ratified Ernst & Young LLP as its independent accounting firm. These decisions follow a strong first quarter for Sotera Health, which exceeded earnings and revenue expectations.
Sotera Health (NASDAQ: SHC) investors back directors, pay and auditor
Sotera Health Company (NASDAQ: SHC) shareholders approved all proposals at their 2026 annual meeting on May 21, 2026. This included the election of four Class III directors, advisory approval of named executive officer compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The results demonstrate strong investor support for the company's governance and executive compensation plan.
Q1 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks
This article analyzes the Q1 2026 earnings for Sotera Health Company (NASDAQ:SHC) and compares its performance to other research tools & consumables stocks. It highlights Waters Corporation as the top performer with significant revenue growth, while Revvity showed the weakest performance against analyst estimates. The piece also briefly touches on broader market shifts from AI and crypto anxieties to geopolitical risks influencing investment decisions.
Sotera Health (SHC) amends First Lien Credit Agreement and reprices term loans
Sotera Health Company (SHC) has amended its First Lien Credit Agreement, repricing approximately $1.416 billion in term loans. This amendment reduces the interest rate spread by 0.25%, with the repriced loans now bearing interest at Adjusted Term SOFR plus 2.25%. The loans also include a 1.00% soft call premium for certain repricing transactions within six months and mature on May 30, 2031.
Sotera Health Announces Secondary Offering of Common Stock
Sotera Health Company announced a secondary offering of 31,838,253 shares of common stock, exclusively offered by affiliates of Warburg Pincus LLC and GTCR LLC. The company itself is not selling any shares and will not receive any proceeds from this offering, but will cover the expenses. Goldman Sachs & Co. LLC is acting as the underwriter for the offering.
JP Morgan Maintains Sotera Health (SHC) Neutral Recommendation
JP Morgan has reiterated its Neutral recommendation for Sotera Health (SHC). No further details about the reasons for this rating or target price are provided in the given content.
Sotera Health Co stock (US8293551086): litigation overhang eases as business focuses on sterilizatio
Sotera Health Co, trading as SHC on Nasdaq, is navigating ongoing litigation and regulatory scrutiny related to its sterilization operations, while maintaining focus on stable demand for its medical device and pharmaceutical sterilization services. The company emphasizes its role as a critical provider of sterilization, lab testing, and advisory services, relying on long-term contracts and high barriers to entry to ensure recurring revenue. Despite legal challenges, its business model benefits from regulatory-driven demand for product safety and its embedded position within healthcare supply chains.
Warburg Pincus exits Sotera Health (NYSE: SHC) stake; reports zero holdings
Warburg Pincus has filed an amended Schedule 13G/A, signaling a complete exit from its stake in Sotera Health Co. As of May 13, 2026, the various Warburg Pincus entities involved no longer own any shares of Sotera Health Common Stock, reducing their beneficial ownership to 0.00 shares or 0.0% of the class. The filing clarifies the complex organizational structure of the Warburg Pincus Reporting Persons, but does not disclose the mechanics or financial terms of the exit.
GTCR exits stake in Sotera Health Co. (SHC) — reports 0 shares owned
GTCR Reporting Persons have fully exited their stake in Sotera Health Co. (SHC), reporting 0 shares beneficially owned as of May 13, 2026. This information was disclosed in an Amendment No. 7 to their Schedule 13G/A filing. The filing indicates a complete divestment by GTCR Investment XI LLC and its associated funds, though it does not provide details on sale mechanics or proceeds.
GTCR funds sell $193.2m Sotera Health Co stock
GTCR funds have sold their entire holding of 12,735,301 shares in Sotera Health Co (NASDAQ:SHC) for approximately $193.2 million through an underwritten public secondary offering. Following this transaction, GTCR entities no longer own any shares in Sotera Health Co. This sale occurred on May 13, 2026, amidst recent news of Sotera Health's strong Q1 2026 financial results and another secondary offering by affiliates of Warburg Pincus LLC and GTCR LLC.
